Skip to main content
Clinical Trials/NL-OMON40689
NL-OMON40689
Recruiting
Not Applicable

Endovascular Renal Sympathetic Denervation using the Boston Scientific Vessix V2 renal denervation system to Improve Heart Failure - IMPROVE-HF-I

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Heart failure
Sponsor
Erasmus MC, Universitair Medisch Centrum Rotterdam
Enrollment
70
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Age \>\=18 years;
  • 2\. Systolic ejection fraction (established on echo) \<35%;
  • 3\. NYHA Class II, III or IV heart failure despite optimal heart failure therapy;
  • 4\. Renal arteries suitable for the proposed treatment;
  • 5\. A glomerular filtration rate of 30ml/min/1\.73m2 or more;
  • 6\. Written informed consent;
  • 7\. The patient agrees to the follow\-up.

Exclusion Criteria

  • 1\. Pregnancy;
  • 2\. Renal artery abnormalities;
  • 3\. Acute heart failure;
  • 4\. A systolic office based blood pressure of \<110mmHg systolic;
  • 5\. Recent (\<3months) stroke or myocardial infarction
  • 6\. Hypertrophic obstructive cardiomyopathy, constrictive pericarditis
  • 7\. The patient has other medical illness (i.e., cancer) that may cause the patient to be non\-compliant with the protocol, confound the data interpretation or is associated with limited life expectancy (i.e., less than one year);

Outcomes

Primary Outcomes

Not specified

Similar Trials